Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Long-Term Debt Repayments (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $48.0 million, a 6898.87% increase, with the full-year FY2025 number at $48.0 million, changed N/A from a year prior.
  • Long-Term Debt Repayments was $3.0 million for Q4 2025 at Lexicon Pharmaceuticals, down from $45.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $45.0 million in Q1 2025 to a low of -$1.1 million in Q4 2023.